NCT02313740已完成不适用
Prospective Cohort Study to Evaluate Safety and Immunogenicity of Butantan´s Fragmented, Inactivated Trivalent Influenza Vaccine in Healthy Adults and Elderly
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 120
- 主要终点
- Vaccine Immunogenicity
研究概览
简要总结
Prospective cohort study to evaluate safety and immunogenicity of the fragmented, inactivated trivalent Influenza vaccine produced at Butantan Institute in healthy adults and elderly. The study will include a total of 120 participants: 60 participants aged 18 to 59 years in the healthy adults group, and 60 participants aged older than 60 years in the elderly group.This study will evaluate the safety of one dose of the fragmented, inactivated trivalent Influenza vaccine in the first 3 days after vaccination, as well as its immunogenicity 21 days after vaccination.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adults, male or female aged 18 to 59
- •Elderly aged 60 years completed and above
- •To be available to participate in the study throughout its duration (approximately 21 days)
- •To have medical indication to be vaccinated against influenza
- •To demonstrate intention to participate in the study, as documented by signature in the study´s informed consent form.
排除标准
- •Evidence of active neurological, cardiac, pulmonary, hepatic or renal disease as clinical history and/or physical examination (except hypertension under control among the elderly)
- •Compromised immune system diseases including: HIV, diabetes mellitus, cancer (except basal cell carcinoma) and autoimmune diseases
- •Behavioral, cognitive or psychiatric disease that in the opinion of the principal investigator or his representative physician, affects the participant ability to understand and cooperate with all study protocol requirements
- •Abusive usage of alcohol or drugs in the past 12 months that has caused medical, professional or family problems, indicated by clinical history
- •Known systemic hypersensitivity to eggs or to any component of the vaccine
- •History of severe adverse reaction after previous administration of an Influenza vaccine within 6 weeks following vaccination
- •History of Guillain-Barre Syndrome or other demyelinating disease
- •Diagnosis of asthma with a history of hospitalization in the last six months due to illness
- •Suspected or confirmed fever in the 3 days prior to vaccination or axillary temperature greater than 37.8 ° C on the day of vaccination
- •Use of corticosteroids (except topical or nasal) or other immunosuppressive drugs within 42 days before study initiation/baseline. It will be considered immunosuppressive dose of corticosteroids the equivalent to a dose ≥10 mg of prednisone per day for over 14 days
- •Impaired coagulation due to chronic disease or due to use anticoagulant medication (warfarin or heparin) in the 7 days preceding vaccination
- •Have received live virus vaccine within 28 days or killed virus vaccine in the last 14 days prior to vaccination, or have a scheduled immunization during the first 21 days after vaccination
- •Have received influenza vaccine in the past 6 months;
- •History of asplenia
- •Have received blood products in the past 6 months, including transfusions or immunoglobulin, or scheduled administration of blood products or immunoglobulin for the first 21 days after vaccination
- •have a counterindication for Influenza vaccination, including allergy to egg proteins
- •Use of any investigational product within 42 days before vaccination;
- •Any other condition that might put in risk the safety/rights of a potential participant or hurdle his/her compliance with this protocol in investigator's opinion or his representative physician.
结局指标
主要结局
Vaccine Immunogenicity
时间窗: 21 days
Antibody response to each of the vaccine´s strains as measured by % seroconversion, increase in the geometric mean of hemagglutination-inhibition (HAI) titers and % seroprotection.
Vaccine safety assessed by unsolicited local and systemic adverse reactions up to 3 days post vaccination
时间窗: 3 days
次要结局
未报告次要终点
研究者
相似试验
已完成
不适用
Prospective cohort study on immunogenicity, safety and efficacy of seasonal influenza vaccination to healthy adults who received non-adjuvanted or AS03A-adjuvanted pandemic influenza H1N1 vaccination one year agoJPRN-UMIN000004631ational Hospital Organization, Tokyo National Hospital100
已完成
3 期
A Study on the Immune Response and Safety of Inactivated Poliovirus Vaccine (IPV) When Co-administered With Human Rotavirus (HRV) Porcine Circovirus (PCV)-Free Vaccine in Healthy Chinese InfantsGastroenteritisNCT06331156GlaxoSmithKline400
已完成
2 期
Immunogenicity and Safety of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine in InfantsInfluenzaNCT01494740Shanghai Institute Of Biological Products312
已完成
2 期
Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly SubjectsOrthomyxoviridae InfectionMyxovirus InfectionInfluenzaNCT00388583Sanofi817
进行中（未招募）
不适用
A Preliminary Exploratory Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants Aged 18 Years and Over in ChinaSARS-CoV-2NCT05547256AIM Vaccine Co., Ltd.54